HWO-2021-Twins-of-the-Year-Awards---header

WFH 2021 Twins of the Year announced

The WFH is happy to announce the 2021 Twins of the Year! The 2021 Hemophilia Organization Twinning (HOT) Program Twins of the Year are Palestine-Venezuela, and the 2021 Hemophilia Treatment Centre Twinning (HTC) Program Twins of the Year award is shared by Addis Ababa (Ethiopia)-Minneapolis (U.S.A) and Tehran (Iran)-Milan (Italy).

Also available in: Français Español 日本語

The WFH Twinning Program creates short-term collaborative partnerships between medical professionals and patient and youth leaders in emerging and established countries for a period of two to four years with the main goal of improving standards of care. The World Federation of Hemophilia (WFH) Twinning Program facilitates “self-sustaining” knowledge by helping organizations increase their learning so that they can, in turn, share best practices with others in their countries, and, eventually, with other organizations around the world.

The 2021 Twins of the Year Awards were announced at the WFH 2022 World Congress in Montreal, Canada. Three partnerships demonstrated their resilience and ability to adapt during another pandemic year, showing their ongoing commitment to improving care and treatment for people with bleeding disorders in their countries.   

The Palestine-Venezuela twins had a memorable year with continued close collaboration at the strategic and operational levels. They also worked together on capacity development to improve organizational structure and governance, and on data collection. The twins also held psychosocial and awareness-raising activities, reaching over 200 people with bleeding disorders and family members. Ahmed R. Al Kashif from Palestine Avenir for Childhood Foundation shared that, “Through various jointly implemented projects, a very positive impact was reflected on lives of hemophilia patients in Palestine.”

Palestine-Venezuela twins

The Addis Ababa (Ethiopia)-Minneapolis (U.S.A) twins also demonstrated their ability to adapt to the challenges presented by the COVID-19 pandemic. Their dedication in Ethiopia resulted in a wonderful partnership despite many unforeseen obstacles in both countries. The team kept its focus on educating healthcare practitioners (HCPs) and ensuring that labs were well equipped to perform diagnostics tests. 

Addis Ababa (Ethiopia)-Minneapolis (U.S.A) twins

The Tehran (Iran)-Milan (Italy) partnership has focused on adapting training materials to the Iran’s cultural, epidemiological and local needs. In their final year, capacity building and the sharing of experiences on the management of patients with hemophilia, inhibitors, and von Willebrand disease (VWD) were priority areas. The twins were able to make significant advances in the accurate diagnosis of people with VWD using different tests, all of which are now available in Tehran. The teams in Tehran and Milan are looking forward to a continued relationship post-twinning.

Tehran (Iran)-Milan (Italy) twins
During the twinning event at the World Congress, the WFH was delighted to recognize the long-standing support of Pfizer for the Twinning Program from 2001 to 2022. The Program has had a significant global impact, with 265 partnerships created across 119 countries.
The support of Pfizer was recognized at the event.

On behalf of the WFH, congratulations to the 2021 Twins of the year!

For more information on the WFH Twinning Program, please click here.

The Twinning program is supported by exclusive funding from Pfizer.

We’ve accomplished a lot this year, we need your help to continue strong.

Would you like to read more about similar articles?

Disclaimer

The information on the WFH website is provided for general information purposes only. The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

While every effort has been made to ensure the accuracy of the information on this site, the WFH does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.

Messages posted to WFH discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.

References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH. The WFH is not responsible and assumes no liability for the content of any linked websites.

Fraud Alert

Unauthorized solicitations – Warning

The WFH has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH staff or falsely stating that they are associated with the WFH. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH, are fraudulent and come from outside of our organization.

If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH emails come from @wfh.org).

We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH at [email protected] or call +1 514-875-7944.

Website privacy policy

The WFH USA does not collect personally identifying information about you when you visit our site, unless you choose to provide such information to us. Providing such information is strictly voluntary. This policy is your guide to how we will handle information we learn about you from your visit to our website.

Use of links

Throughout our website, we provide links to other servers which may contain information of interest to our readers. We take no responsibility for, and exercise no control over, the organizations, views, or accuracy of the information contained on other servers. When linking to the WFH USA, we request that you ensure that there are no associated connections for commercial purposes. Any official use of the name WFH USA or the use of its logo needs to be approved by the WFH USA. If you have a link you’d like us to consider adding to our website, please send an email to [email protected] with the subject “Link request.”

Use of text and images

All information, photographs, graphics, and other material on this website are protected by copyright. While users of this website may use the content for personal, non-commercial use, none of the content of this website can be modified, translated, transferred or sold, copied, reproduced, published, or distributed, in whole or in part, without the prior written consent of the WFH USA. To view a copy of the WFH USA’s permissions guidelines, click here.

The WFH USA encourages the dissemination of its information and welcomes proposals on the reprinting, redistribution, and translation of its materials. If you would like to publish information that you find on our website, please send your request to [email protected].

Accessibility

If you have suggestions on how to make the site more accessible, please contact us at [email protected].

Opt-Out or Change Your Contact Information

Our website provides users the opportunity to opt-out of receiving communications from us through a special online form or via the communication they have received. You may, at all times, choose to receive which communications within the organization you can receive or none at all. You may also update your contact information previously provided to us via another online form.

Questions about our policies

If you have any questions about this privacy statement, the practices of this site, or your dealings with this website, you can contact us at [email protected].

Functional Scales

The outcomes of interest collected by the WBDR include demographic characteristics, clinical and treatment-related outcomes, burden of disease outcomes, and patient-reported outcomes.

The WBDR includes five functional scales as part of its extended data set:

WBDR hemophilia data sets

WBDR Minimal Data Set

The WBDR Minimal Data Set (MDS) is a set of data on demographics, diagnosis, symptoms and treatment which are collected on patients participating in the WBDR.

WBDR Extended Data Set

The WBDR Extended Data Set (EDS) is a larger set of data, with more details than the MDS, which includes questions on patient demographics, diagnosis, symptoms, treatment and burden of disease. The EDS can be used by hemophilia treatment centers to collect data on patients participating in the WBDR. The WBDR Extended Data Set (EDS), was added to the database in March 2019.